Ameluz-based photodynamic therapy achieved higher clearance rates in superficial basal cell carcinoma compared to placebo, with significant clinical and histological results. The study involved 187 ...

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its ...

WOBURN, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...

WOBURN, MA / ACCESSWIRE / January 9, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that the first ...

Non-melanoma skin cancer includes BCC, SCC, and the rare MCC, with BCC being the most common and MCC the most aggressive. Diagnosis involves skin examination and biopsy, with additional tests for MCC ...

A new personalized skin cancer treatment is showing success in preventing the return of high-risk melanoma. Five-year study results were announced on Tuesday by pharmaceutical companies Moderna Inc ...

Actinic keratosis (AK) is a common precancerous lesion arising from cumulative ultraviolet exposure, often heralding the development of non-melanoma skin cancers such as basal cell carcinoma and ...

WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of PDT, ...